» Articles » PMID: 15172753

Hereditary Breast and Ovarian Cancer in Cyprus: Identification of a Founder BRCA2 Mutation

Overview
Date 2004 Jun 3
PMID 15172753
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The entire coding regions of the two breast cancer susceptibility genes BRCA1 and BRCA2 from breast cancer patients from 40 Cypriot families with multiple cases of breast and ovarian cancer were sequenced. A total of four protein-truncating mutations were found in six families. In BRCA1, a novel truncating mutation 5429delG was found in exon 21. In BRCA2, three truncating mutations were detected: a frameshift 8984delG in exon 22 and two nonsense mutations C1913X in exon 11 and K3326X in exon 27. It is noted that mutation 8984delG was found in three separate families, and haplotype analysis showed that this may be a founder mutation in the Cypriot population. In addition, a pair of rare variants, Q356R and S1512I, was detected in BRCA1 in patients belonging to two Cypriot families. The simultaneous presence of this pair of missense mutations may be associated with the breast cancer phenotype in the Cypriot population. We conclude that the BRCA2 gene appears to play a more important role in familial breast cancer in the Cypriot population than BRCA1.

Citing Articles

Prognostic Factors Influencing Survival in Ovarian Cancer Patients: A 10-Year Retrospective Study.

Andreou M, Kyprianidou M, Cortas C, Polycarpou I, Papamichael D, Kountourakis P Cancers (Basel). 2023; 15(24).

PMID: 38136256 PMC: 10742060. DOI: 10.3390/cancers15245710.


Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls.

Zanti M, Loizidou M, OMahony D, Dorling L, Dennis J, Devilee P Front Genet. 2023; 14:1248492.

PMID: 37790698 PMC: 10544326. DOI: 10.3389/fgene.2023.1248492.


Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

ElBiad O, Laraqui A, El Boukhrissi F, Mounjid C, Lamsisi M, Bajjou T BMC Cancer. 2022; 22(1):208.

PMID: 35216584 PMC: 8876448. DOI: 10.1186/s12885-022-09181-4.


The contribution of Cyprus to non-communicable diseases and biomedical research from 2002 to 2013: implications for evidence-based health policy.

Pallari E, Lewison G, Pallari C, Samoutis G, Begum M, Sullivan R Health Res Policy Syst. 2018; 16(1):82.

PMID: 30119676 PMC: 6098664. DOI: 10.1186/s12961-018-0355-4.


Mutations in context: implications of BRCA testing in diverse populations.

Felix G, Zheng Y, Olopade O Fam Cancer. 2017; 17(4):471-483.

PMID: 28918466 PMC: 5980658. DOI: 10.1007/s10689-017-0038-2.